Emmaus Medical
  • CEO Letters
  • Overview
    • Mission
    • Leadership
      • Management Team
      • Board of Directors
    • Corporate Compliance
    • Corporate Governance
  • Products
    • Endari
  • Pipeline
    • Research Publications
    • Diverticulosis
    • Cell Sheet Engineering
  • News
    • Press Releases
    • Media Contacts
    • Media Kit
  • Investors
  • Career
  • Contact Us

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
    • Pre-merger Emmaus Life Science SEC Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts

Emmaus Life Sciences Announces Submission of Marketing Authorization Application to Swissmedic Ideogen, A.G. to Manage Early Access Program

Jun 15, 2021 11:21am EDT

Emmaus Life Sciences Announces Submission of Marketing Authorization Application for Endari® to the Saudi Food & Drug Authority

May 26, 2021 12:19pm EDT

Emmaus Life Sciences Reports Annual Financial Results for 2020 and Provides Updated Business Review

May 04, 2021 9:30am EDT

Emmaus Life Sciences Provides Form 10-K Filing Update

Apr 15, 2021 2:16pm EDT

Emmaus Life Sciences Announces Collaboration with Kainos Medicine for Preclinical Development of IRAK4 Inhibitor as Potential Anti-Cancer Drug

Mar 02, 2021 11:44am EST

Emmaus Life Sciences Reports Increase in Sales Volume in 2020

Jan 27, 2021 11:30am EST

Emmaus Life Sciences Reports Annual Financial Results for 2019 and Provides Business Review

Jan 25, 2021 12:13pm EST

Michigan Revises Prior Authorization Criteria for Endari®

Dec 10, 2020 11:30am EST

Emmaus Life Sciences Launches Endari® Support Program

Dec 08, 2020 11:30am EST

Endari® Granted Orphan Drug Status in Switzerland

Dec 03, 2020 11:20am EST
RSS
  • Prev
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • ...17
    Next
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed

    Emmaus Medical, Inc. Registered ® Emmaus Medical, Inc, Torrance, CA. All rights reserved.

    • Privacy
    • Terms of Use
    • Contact